Inve US ▾
BLBLLN

BillionToOne (BLLN) Q2 FY26 earnings call

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

BillionToOne delivered a strong quarter, showcasing robust revenue and volume growth alongside impressive profitability and margin expansion, driven by its innovative QCT technology platform. The company continues to invest strategically in product development and commercial expansion, including new prenatal and oncology offerings and EMR integration, positioning for accelerated growth in the coming quarters. Despite some short-term impacts from true-up timing and held claims, management remains confident in its long-term trajectory and ability to maintain profitability.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

BLLN operating KPIs by quarter

BLLN operating KPIs stated on its earnings calls, by fiscal quarter
KPI Dec 2025 Q4 FY25 Mar 2026 Q1 FY26This call Jun 2026 Q2 FY26Change vs prior quarter
Procedures
~170K Our leadership in product innovation and our growing commercial team continue to drive our test volume with Q4 reaching approximately 170,000 tests, a 47% year-over-year increase. Source: earnings call transcript
~188K In Q1, we delivered approximately 188,000 tests, representing 44% year-over-year growth and strong sequential growth across both product lines, with prenatal volumes growing approximately 10% quarter-over-quarter and oncology volumes growing approximately 25% quarter-over-quarter. Source: earnings call transcript
——
Average selling price
$561 Overall ASP increased another 12% quarter-over-quarter from $501 to $561, a significant $60 per test increase in a single quarter. Source: earnings call transcript
$571 As our ASPs increased 28% year-over-year to $571 per test and as we maintained our COGS at $153 per test despite the higher proportion of oncology tests that have a higher COGS, we expanded our gross margins to 73% in Q1, a strong 9 percentage point increase year-over-year. Source: earnings call transcript
$551 Overall ASP increased 21% year-over-year to $551 per test. Source: earnings call transcript
-3.5%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.